A Multiple-Dose Study of LY3502970 in Healthy Participants

NCT05110794 · Completed

Last updated 2026-05-28

This clinical trial tested different doses of the drug LY3502970 in healthy adults to measure how the body absorbs and processes the medication.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 34 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2021-11 · est. completion 2022-02

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT05110794 ↗

Description as written by the study sponsor.

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.

Treatments tested

LY3502970 Drug

Administered Orally.

Main thing measured	PK: Maximum Observed Concentration (Cmax) of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05110794 ↗